These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34160771)

  • 1. Immunotherapy in AML: a brief review on emerging strategies.
    Moeinafshar A; Hemmati S; Rezaei N
    Clin Transl Oncol; 2021 Dec; 23(12):2431-2447. PubMed ID: 34160771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic cancer vaccine therapy for acute myeloid leukemia.
    Wu M; Wang S; Chen JY; Zhou LJ; Guo ZW; Li YH
    Immunotherapy; 2021 Jul; 13(10):863-877. PubMed ID: 33955237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.
    Rotiroti MC; Arcangeli S; Casucci M; Perriello V; Bondanza A; Biondi A; Tettamanti S; Biagi E
    Hum Gene Ther; 2017 Mar; 28(3):231-241. PubMed ID: 27967241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches.
    Tosic N; Marjanovic I; Lazic J
    Biochem Pharmacol; 2023 Sep; 215():115705. PubMed ID: 37532055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immunotherapy for refractory hematological malignancies.
    Reagan JL; Fast LD; Safran H; Nevola M; Winer ES; Castillo JJ; Butera JN; Quesenberry MI; Young CT; Quesenberry PJ
    J Transl Med; 2013 Jun; 11():150. PubMed ID: 23782682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of various interleukins in acute myeloid leukemia.
    Kaser EC; Zhao L; D'mello KP; Zhu Z; Xiao H; Wakefield MR; Bai Q; Fang Y
    Med Oncol; 2021 Apr; 38(5):55. PubMed ID: 33835290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
    Gbolahan OB; Zeidan AM; Stahl M; Abu Zaid M; Farag S; Paczesny S; Konig H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.
    Isidori A; Salvestrini V; Ciciarello M; Loscocco F; Visani G; Parisi S; Lecciso M; Ocadlikova D; Rossi L; Gabucci E; Clissa C; Curti A
    Expert Rev Hematol; 2014 Dec; 7(6):807-18. PubMed ID: 25227702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for pediatric acute myeloid leukemia.
    Bonifant CL; Velasquez MP; Gottschalk S
    Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
    Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
    Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in immunotherapy for acute myeloid leukemia.
    Przespolewski A; Szeles A; Wang ES
    Future Oncol; 2018 Apr; 14(10):963-978. PubMed ID: 29542352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
    Stahl M; Goldberg AD
    Curr Oncol Rep; 2019 Mar; 21(4):37. PubMed ID: 30904967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy prospects for acute myeloid leukaemia.
    Barrett AJ; Le Blanc K
    Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies in immunotherapy for acute myeloid leukemia.
    Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
    Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.